Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Superficial cervical plexus block with ropivacaine in oncologic head and neck surgery
2024-510942-15-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in head and neck cancer (HNC) comparing Ropivacaine superficial cervical plexus block with Sodium chloride control block (2 arms). Primary endpoint: Postoperative morphine consumption. Planned start Apr 2026; status: authorised.
02
Drugs
ropivacainesodium chloride
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on 2024-510942-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510942-15-00.